Replies to post #40755 on Ariad Pharmaceuticals Inc fka ARIA

[grandma_of_jbraika]

FMR continues to buy and hold ARIA after the big plunge, which indicates the largest mutual fund is very confident on Ariad, at least it seems to me.

...This may explain why certain funds, like Sarissa, have been accumulating the stock after the big plunge.

Sarissa bought 11.5 million shares; Camber Capital 10 million shares; FMR added 7.8 million shares, totally holding 27,392,509 shares.

FMR has been the No. 1 institutional holder of ARIA since the 1st quarter of 2000.

I thought FMR would sell all on the Oct. 9 bad news as it did in 1999 because of Ariad's big financial problem. It has turned out that Fidelity keeps buying and holding this stock.

Fidelity is confident on Ariad, isn't it?
--------
If Fidelity joins a class action lawsuit against Ariad, it may get as much as $273,925.09. LOL!

Grandma_of_jbraika: "I hope the law firm might help me get $0.001 per 1,000 shares that are qualified for the class action."

zipjet: "That is a bit low. You might get ten times that.

[Euripides90]

I'm hoping Monday's presentations will give a bounce to over $5.00 again and then it will settle in above that range to at least $6.00.
From BarChart:

Ariad Pharmaceuticals (ARIA)

4.07-0.50 (-10.94%) 8:13P EST (NASDAQ)
Detailed Opinion as of Fri, Dec 6th, 2013 View Help

Show Signal Strength and Direction
Composite Indicators Signal
Get Chart Get Performance

TrendSpotter Buy

Short Term Indicators
Get Chart Get Performance

7 Day Average Directional Indicator Buy

More HOLDs after the next week: let's see if this is correct and
there is a significant correction to the drop last week.


MarketWatch's analyst consensus at $7.44 is much higher than what we're seeing on some scoreboards elsewhere,
taking into account that even with setbacks quarterly and annual revenues are expected to increase.

The company's announced budget-savings plans apparently meet with analysts' satisfaction however, of course it would be nice to regain the full potential and be able to continue development of all the promising molecules in the pipeline.
Would of course be ideal if some rumors about partnering bear out.

Just trying to balance all the doom and gloom while being realistic within the context of numbers!
Waiting for reviews of the presentations.


Snapshot
Average Recommendation: Hold
Average Target Price: 7.44

Number of Ratings: 22

Current Quarters Estimate: -0.46
FY Report Date: 12 / 2013
Current Year's Estimate: -1.56
Last Quarter's Earnings: -0.36
Median PE on CY Estimate: 9,999

Year Ago Earnings: -1.33
Next Fiscal Year Estimate: -1.00
Median PE on Next FY Estimate: 9,999